GPX4 and cancer: Indeed, the research from Weimin Wang and colleagues has shown that the combination of GPX4 inhibitor, cyst(e)inase with PD-L1 blockade, can improve T cell-induced antitumor immunity and ferroptotic death of cancer cells synergistically [345].